Scholar calls for FDA to remove stringent restrictions on medication abortion.
Anti-abortion advocates take aim at FDA approval and regulation of the abortion drug mifepristone, threatening access nationwide.
Scholar argues that Congress and FDA should treat risky clinical artificial intelligence tools as medical devices.
FDA’s approach to evidence-based decision-making may not be addressed to the right people.
Experts contend that FDA clinical trials fail to ensure adequate consideration of women’s health needs.
Exploring FDA’s toolkit for encouraging study sponsors to meet diversity goals.
Scholar highlights the fragmented regulatory environment governing advanced neurological technology.
Two scholars find that the removal of FDA health warnings prompts an increase in drug marketing.
Scholars explore regulatory approaches to artificial intelligence in the health care sector.
The CDC should recommend agricultural reforms to reduce pandemic risks caused by factory farms.
Despite delayed government action, manufacturers can do more to reduce toxic metals in baby food.
Scholars consider how the authorization of telehealth can expand access to medication abortion.